May affect large bile ducts (both intra- and extrahepatic), small bile ducts, or both
Etiology/Pathogenesis
•
Unknown etiology
Frequent association with inflammatory bowel disease, particularly ulcerative colitis
Clinical Issues
•
Predilection for young and middle-aged men
•
Majority of patients are asymptomatic at diagnosis
•
Elevated alkaline phosphatase in over 90% of patients
•
Progresses to biliary cirrhosis in majority of patients within 10-15 years
•
Essentially no effective medical therapy
Liver transplantation for end-stage liver disease
•
Increased risk of cholangiocarcinoma, colorectal carcinoma, and gallbladder carcinoma
Imaging
•
Cholangiography is diagnostic gold standard
Characteristic beaded appearance of biliary tree secondary to segmental strictures
Microscopic
•
Findings often patchy and nonspecific, making biopsy diagnosis difficult
Concentric fibrosis around affected bile ducts with onion skin appearance
–
Present only in minority of biopsy samples
•
Lymphocytic cholangitis
•
Degeneration and atrophy of duct epithelium
Eventual obliteration of ducts with variable scarring
•
Periportal copper deposition indicates chronic cholestasis
TERMINOLOGY
Abbreviations
•
Primary sclerosing cholangitis (PSC)
Definitions
•
Chronic cholestatic disease featuring progressive inflammation and fibrosis of intrahepatic and extrahepatic biliary tree
ETIOLOGY/PATHOGENESIS
Unknown
•
Frequent association with HLA-B8 and DR3
100x increased risk of disease in 1st-degree relatives of patients with PSC
•
Associated with chronic idiopathic inflammatory bowel disease (IBD), particularly ulcerative colitis
∼ 70% of patients with PSC have ulcerative colitis
2.0-7.5% of patients with ulcerative colitis have PSC
1.4-3.4% of patients with Crohn disease have PSC
•
May affect large bile ducts (both intra- and extrahepatic), small bile ducts, or both
CLINICAL ISSUES
Epidemiology
•
Incidence
∼ 1 in 100,000 people
–
Highest in people with Northern European ancestry
•
Age
Any age, common from 20-50 years
•
Sex
Close to 70% of patients are male
Presentation
•
Majority of patients are asymptomatic at diagnosis
Diagnosis often results from investigation of abnormal liver tests
•
Nonspecific signs/symptoms
Fatigue
Abdominal pain
Pruritus/jaundice
Weight loss
Laboratory Tests
•
Elevated alkaline phosphatase in > 90% of patients
•
Transaminases may be 2-3x normal limits but may not be elevated
•
Bilirubin typically normal at diagnosis
Elevation more common in advanced disease
•
Nonspecific antibodies often present including ANA, SMA, ANCA
Treatment
•
Essentially no effective medical therapy
Use of ursodeoxycholic acid controversial
•
Endoscopic balloon dilation or stenting
•
Liver transplantation for end-stage liver disease
Reportedly recurs in up to 1/2 of transplant recipients within 10 years
Prognosis
•
Progresses to biliary cirrhosis in majority of patients within 10-15 years
Slightly < 20% of asymptomatic patients have cirrhosis at time of diagnosis
•
Increased risk of cholangiocarcinoma
160x higher than general population
Risk factors include older age at PSC diagnosis, smoking, alcohol use, longer duration of IBD
Surveillance is recommended (imaging and serum CA19-9 level)
–
Effectiveness of surveillance is unclear
•
Increased risk of gallbladder carcinoma
2% of patients with PSC